Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 528

1.

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group.

Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9.

2.

Rolf Ackermann (1941-2015): European urologist and gentleman.

Boccon-Gibod L.

Eur Urol. 2015 Jun;67(6):1198-9. doi: 10.1016/j.eururo.2015.03.025. Epub 2015 Mar 23. No abstract available.

PMID:
25944040
3.

Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.

Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F.

Eur Urol. 2014 Oct;66(4):655-63. doi: 10.1016/j.eururo.2014.05.037. Epub 2014 Jun 18.

PMID:
24954791
4.

Pulmonary alveolar proteinosis in children on La Réunion Island: a new inherited disorder?

Enaud L, Hadchouel A, Coulomb A, Berteloot L, Lacaille F, Boccon-Gibod L, Boulay V, Darcel F, Griese M, Linard M, Louha M, Renouil M, Rivière JP, Toupance B, Verkarre V, Delacourt C, de Blic J.

Orphanet J Rare Dis. 2014 Jun 14;9:85. doi: 10.1186/1750-1172-9-85.

5.

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Crawford ED, Shore ND, Moul JW, Tombal B, Schröder FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Klotz L.

Urology. 2014 May;83(5):1122-8. doi: 10.1016/j.urology.2014.01.013. Epub 2014 Mar 22.

PMID:
24661333
6.

Malformations, genetic abnormalities, and Wilms tumor.

Dumoucel S, Gauthier-Villars M, Stoppa-Lyonnet D, Parisot P, Brisse H, Philippe-Chomette P, Sarnacki S, Boccon-Gibod L, Rossignol S, Baumann C, Aerts I, Bourdeaut F, Doz F, Orbach D, Pacquement H, Michon J, Schleiermacher G.

Pediatr Blood Cancer. 2014 Jan;61(1):140-4. doi: 10.1002/pbc.24709. Epub 2013 Aug 23.

PMID:
23970395
7.

miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.

Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K, O'Sullivan M.

PLoS One. 2013;8(1):e53417. doi: 10.1371/journal.pone.0053417. Epub 2013 Jan 7.

8.

Standardization of Gleason grading among 337 European pathologists.

Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P.

Histopathology. 2013 Jan;62(2):247-56. doi: 10.1111/his.12008.

PMID:
23240715
9.

[Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management].

Coloby P, Boccon-Gibod L, Coulange C, Culine S, Davin JL, Richaud P, Zerbib M, Soulié M.

Prog Urol. 2012 Sep;22 Suppl 2:S29-30. doi: 10.1016/S1166-7087(12)70033-7. French. No abstract available.

PMID:
23098787
10.

Molecular therapy is advancing with drugs that target pathways relevant for several cancers. Foreword.

Boccon-Gibod L.

BJU Int. 2012 Oct;110 Suppl 1:1-2. doi: 10.1111/j.1464-410X.2012.11427.x. No abstract available.

11.

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE.

Urology. 2012 Jul;80(1):174-80. doi: 10.1016/j.urology.2012.01.092.

PMID:
22748873
12.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

13.

Utility of whole slide imaging and virtual microscopy in prostate pathology.

Camparo P, Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Oliveira P, Vainer B, Varma M.

APMIS. 2012 Apr;120(4):298-304. doi: 10.1111/j.1600-0463.2011.02872.x. Review.

PMID:
22429212
14.

Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France.

Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.

PMID:
22036776
15.

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

Boccon-Gibod L, van der Meulen E, Persson BE.

Ther Adv Urol. 2011 Jun;3(3):127-40. doi: 10.1177/1756287211414457.

16.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.

J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23.

PMID:
21788033
17.

Identification of a complex 17q rearrangement in a metanephric stromal tumor.

Toutain J, VuPhi Y, Doco-Fenzy M, Morice-Picard F, Stanislas S, Laharanne E, Cailley D, Vergnes P, Perel Y, Boccon-Gibod L, Deminiere C, Taine L.

Cancer Genet. 2011 Jun;204(6):340-3. doi: 10.1016/j.cancergen.2011.05.003.

PMID:
21763632
18.

Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.

Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lockwood G, Lopez-Beltran A, Montironi R, Oliveira P, Schwenkglenks M, Vainer B, Varma M, Verger V, Camparo P.

Virchows Arch. 2011 Aug;459(2):175-82. doi: 10.1007/s00428-011-1106-x. Epub 2011 Jun 23.

PMID:
21698392
19.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.

J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.

20.

Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, Varma M, Egevad L.

Histopathology. 2011 Mar;58(4):579-85. doi: 10.1111/j.1365-2559.2011.03784.x. Epub 2011 Feb 23.

PMID:
21348893

Supplemental Content

Loading ...
Support Center